1370426-46-2

Upstream product

• 79175-35-2 3,4-dichlorophenylmagnesium bromide 
• 912468-67-8 tert-butyl 6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 1370426-83-7 tert-butyl 6-((3,4-dichlorophenyl)(methoxyimino)methyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 1370426-80-4 tert-butyl 6-(3,4-dichlorobenzoyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 1370426-79-1 tert-butyl 6-((3,4-dichlorophenyl)hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate 

Downstream Products

• 1370426-48-4 3-azabicyclo[3.1.0]hexan-6-yl(3,4-dichlorophenyl)methanone O-methyl oxime 

Relevant academic research and scientific papers

NOVEL BICYCLIC COMPOUNDS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).